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Introduction 
1.The bio-psycho-social model of illness encourages healthcare practitioners to 
think beyond anatomy and physiology to consider how the interplay of mind, 
body and social circumstances affect health and wellbeing. Medicine has much 
to offer in treating the biological aetiology of illness and recent commitments to 
parity of esteem are expected to give equal priority to addressing social, 
psychological and physical aspects of health. To date, however, the capacity for 
healthcare practitioners to address the social problems that precipitate and 
perpetuate ill health have been limited. Social prescribing is a means by which 
healthcare professionals seek to address the non-medical causes of ill health 
with non-medical interventions.  
2.It is estimated that around 20% of patients consult their general practitioner (GP) 
for what is primarily a social problem (Low Commission, 2015). It has been 
suggested that referral to a social prescribing service could reduce this pressure. 
This paper critically appraises the current evidence as to whether social 
prescribing reduces the demand for health services and is cost effective.  
Method 
3.A systematic search for papers was conducted on major online databases and 
further evaluations were assimilated from key opinion leaders. The criteria for 
inclusion were to: a) be UK-based, b) describe a social prescribing service that 
involved referral of a patient from primary care to a ‘link worker’ who would 
connect the patient with relevant non-medical interventions in the third sector 
and c) report either i) quantitative data on demand for healthcare services and/or 
ii) evaluation of social and economic impact of social prescribing.  
Results 
4.Of the 94 project reports identified from the systematic search, 14 papers met 
the criteria set out in the method. Of these, only one was a randomised 
controlled trial (Grant et al, 2000) and two included a matched controlled group 
(Bertotti et al, 2015; Maughan et al, 2015). 
5.Seven papers looked at the effect on demand for General Practice, reporting an 
average 28% reduction in demand for GP services following referral. Results 
ranged from 2% (Kimberlee et al, 2014) to 70% (Longwill, 2014). 
6.Five studies (Kimberlee, 2016; Dayson and Bashir, 2014; Bertotti et al, 2015; 
Farenden et al, 2015; Kimberlee et al, 2014) looked at the effect on Accident  
and Emergency (A&E) attendances reporting an average 24% fall in attendance 
following referral. Results ranged from 8% (Kimberlee et al, 2014) to 26.8% 
(Farenden et al, 2015).  
7.Five studies looked at the effect on demand for other secondary care services 
(Palmer et al, 2017; Kimberlee, 2016; Dayson and Bashir, 2014; Farenden et al, 
2015; Brandling et al, 2011). Three reported a fall in emergency hospital 
admissions in the months following referral (6% (Kimberlee, 2016), 7% (Dayson 
and Bashir, 2014) and 33.6% (Farenden et al, 2015)) and two studies measured 
secondary care referrals after social prescribing. One reported statistically 
significant drops in secondary care referrals at 12 months (55%) and 18 months 
(64%) (Brandling et al., 2011) and the other projected reductions in demand of 
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0.1 consultant psychiatrists per annum per patient and 0.2 Community Mental 
Health Team nurse consultations per annum per patient (Longwill, 2014). 
However, in contrast, one study showed that the likelihood of referral to 
secondary mental health care more than doubled after referral. (Grayer et al, 
2008)  
8.Eight studies calculated value for money assessments such as cost benefit 
analysis (Burgess, 2014; Windle et al., 2016). None of the studies used the 
traditional cost-effectiveness or full cost-utility analysis. Estimates varied widely 
from an annual Return on Investment (ROI) of 0.11 (in the first year of 
operations) (Dayson and Bashir, 2014) to 0.43 (Kimberlee, 2016). The 
randomised controlled trial reported higher cost of care per patient in the 
intervention group than the control, though no value for money assessments 
were calculated (Grant et al, 2000).  
9.Four studies carried out broader Social Return on Investment (SROI) 
calculations. SROI puts an estimated monetary value on the sum of benefits 
accruing to all stakeholders, not just the NHS. Studies varied in the combination 
of stakeholders and benefits selected for inclusion in SROI calculations. Patients, 
Local Authorities (LAs) and the Department of Work and Pensions (DWP) were 
commonly cited stakeholders. Improved mental wellbeing outcomes and higher 
rates of employment were examples of positive externalities considered in SROI 
but excluded from ROI analysis. The mean SROI (Weld et al, 2015) was £2.3 
per £1 invested in the first year (Kimberlee, 2016).  
Discussion 
10. Demand data presents a mixed picture. In the case of GP attendance and 
secondary care referrals, findings were contradictory. In the case of A&E 
attendance, findings were spread over a wide range. Both points raise issues 
about consistency of findings. Despite this, for the most part, social prescribing 
was reported to have a protective effect on service demand, though the extent of 
this impact needs to be contextualised.  
11. Any reported reduction in demand for health services applies only to the 
cohort of patients referred to social prescribing, and in one study, only for sub-
groups who completed the interventions. In some cases, patients who failed to 
engage fully with social prescribing had much higher rates of health service use 
both before and after referral (Dayson and Bashir, 2014). This point is pertinent to 
value assessments.  
12. Firstly, it implies that the service could achieve greater value for money if it 
were better targeted on the population that completes and responds to it. 
Secondly, it raises questions about the marginal utility that social prescribing 
provides in relation to other services designed to reduce demand on services. 
Given a finite budget, a more effective use of resources might be to commission 
more targeted interventions designed for the population of patients placing the 
greatest burden on services (Bertotti et al, 2015).  
13. The quality of the data also means that results need to be interpreted with 
caution. The number of evaluations meeting the inclusion criteria was small. Only 
one of the studies was a randomised controlled trial (Grant et al, 2000) and few 
were published in peer-reviewed journals. Evaluations were often subject to high 
drop-off rates at follow-up meaning these studies had reduced power to show a 
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statistically significant outcome. In some cases, statistical significance was not 
discussed at all. Where a high number of patients were lost to follow up, studies 
were at risk of bias as predominantly patients who had completed the intervention 
gave feedback.  
14. Most studies sought to determine the effect of social prescribing on demand 
by comparing rates of use before and after referral, rather than between a control 
and an intervention group. This does not truly isolate the effect of the intervention 
as it fails to eliminate the impact of what would have occurred anyway over time. It 
is also important to note that no conclusions can be made about the long-term 
impact of social prescribing, as the time to follow up was often short.  
15. The quality of ROI estimates suffered from a lack of accurate data to inform 
the calculations. Some studies used only patient reported use of services or GP 
reports of perceived drops in demand, both of which are subject to recall bias in 
these non-blinded trials leading to potentially inaccurate estimates.  One paper 
had extrapolated their demand figures from the results of similar studies in other 
parts of the UK, which is at risk of inaccuracy (Farenden et al, 2015).  
16. SROI calculations used inconsistent combinations of potential benefits making 
it difficult to compare studies based on SROI as they did not always compare like 
with like. 
Conclusion  
17. In conclusion, the evidence for social prescribing is broadly supportive of its 
potential to reduce demand on primary and secondary care. The quality of that 
evidence is weak, however, and without further evaluation, it would be premature 
to conclude that a proof of concept for demand reduction had been established. 
Similarly, the evidence that social prescribing delivers cost savings to the health 
service over and above operating costs is encouraging but by no means proven or 
fully quantified. 
18. Despite these findings, social prescribing continues to grow in scope and 
scale across the UK. There are a number of possible reasons for this. 
19. Link worker social prescribing schemes often include a number of 
interventions, some of which are evidence-based and some of which are not. The 
success or otherwise of a link worker model will depend on the combined success 
of each intervention. It may be disingenuous therefore, to conclude that paucity of 
evidence to support the effectiveness of a link worker model implies paucity of 
evidence for individual interventions. These interventions may still be worthwhile 
uses of healthcare resources and this could explain their persistence and growth 
in the UK.  
20. Equally, paucity of evidence to support the link worker model should not 
preclude further evaluation of it. It is more challenging to gain the standard of 
evidence for complex interventions that is routinely expected of simpler ones. In 
fact, the standard of evidence to date on the link worker social prescribing model 
is approximately the standard expected for a complex intervention at this stage in 
its development (Craig et al, 2006).   
21. Another reason why social prescribing continues to grow, despite 
shortcomings in the quality of evidence to support demand reduction, may be the 
effect that social prescribing reportedly has on the health and wellbeing of 
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patients. The social prescribing narrative is compelling and much of the qualitative 
evidence shows that these services are very well liked by patients and GPs alike 
(Smith and Skivington, 2016).  
22. Furthermore, in an increasing proportion of projects, the cost of funding is 
shared with external stakeholders to the NHS (Kimberlee, 2016). Sharing the cost 
of social prescribing improves ROI and makes it a more affordable and worthwhile 
intervention for the health service to consider. It also makes sense to the non-
NHS stakeholder, if sufficient benefits of social prescribing accrue to them too. 
Joint funding may thus make social prescribing link worker projects such as these 
more likely to proceed and become more embedded in local communities.  
23. The sum of all benefits accruing to all stakeholders is presented in the Social 
Return on Investment (SROI) figures and makes the case for either joint funding 
or subsidy of the projects to realise maximum positive externalities. For this 
reason, a growing proportion of social prescribing projects are now jointly 
developed and funded between Clinical Commissioning Groups and local 
government. This arrangement recognises the unique place that social prescribing 
has, sitting at the true interface of health and social care.  
Recommendations 
24. Without much in the way of ‘top-down’ instruction from national bodies, social 
prescribing has emerged organically ‘from the bottom up’. The most productive 
role for a national body at this point would be to steer the evolution of social 
prescribing to ensure that what spreads, works. For this to happen, the quality of 
evidence needs to be improved and the benefits presented in a consistent format 
to allow clear comparison. This would be achieved through encouraging more and 
better evaluations of on-going projects and helping to develop a common 
evaluation framework to assess impact and draw clear comparisons of 
effectiveness.  
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